Lexicon Pharma (LXRX) Announces FDA Approval of INPEFA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/28/2023
- Wall St ends slightly higher after mixed Fed statements
- Charlie Munger dies at 99
- Barclays raises 2024 S&P 500 price target but warns stocks are 'moving too far, too fast'
- Stocks rise as dollar falls, gold rallies on Fed commentary
- Micron (MU) raises forecast on improved supply/demand balance and pricing
- Berkshire Hathaway (BRK.B): Charlie Munger has died
- BofA examines possible ArcelorMittal takeover of U.S. Steel
- Tesla (TSLA) exec releases Cybertruck event details
- Elliott Sends Letter to the Board of Crown Castle Inc. (CCI), Calls for Operational and Strategic Review of Fiber Business
- L3Harris Technologies (LHX) to Sell its Commercial Aviation Solutions Business to TJC for $800M
Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure
May 26, 2023 4:05 PM EDTINPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes
INPEFA reduced the risk of total occurrence of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits by 33% compared to placebo in the SOLOIST-WHF study
Conference Call and Webcast on Tuesday, May 30, 2023, at 8:00 am Eastern Time
THE WOODLANDS, Texas, May 26, 2023 (GLOBE NEWSWIRE) --... More
